Flodgren P, Sjögren H O
Cancer Immunol Immunother. 1985;19(1):28-34. doi: 10.1007/BF00199308.
The histamine-2 receptor antagonist cimetidine (10(-5)M) and the prostaglandin synthesis inhibitor indomethacin (10(-8)M) augmented natural killer cell activity in the majority of healthy controls and patients with advanced melanoma and in a lower frequency of patients with colorectal carcinoma. Antibody-dependent cellular cytotoxicity was increased in most melanoma patients but in a lower proportion of patients with colorectal cancer. Compared with the effect of interferon the augmentation of NK- and K-cell activities was small in most patients. Cimetidine was also demonstrated to bring about a further increase in the interferon-induced NK activation of peripheral blood mononuclear cells from a majority of healthy donors and patients with melanoma. Furthermore, cimetidine augmented the interferon-induced K-cell activation of peripheral blood mononuclear cells from most patients with melanoma and colorectal cancer.
组胺-2受体拮抗剂西咪替丁(10⁻⁵M)和前列腺素合成抑制剂吲哚美辛(10⁻⁸M)可增强大多数健康对照者、晚期黑色素瘤患者以及较低比例的结直肠癌患者的自然杀伤细胞活性。在大多数黑色素瘤患者中,抗体依赖性细胞毒性增加,但在结直肠癌患者中的比例较低。与干扰素的作用相比,大多数患者中自然杀伤细胞和杀伤细胞活性的增强幅度较小。西咪替丁还被证明可使大多数健康供者和黑色素瘤患者外周血单个核细胞的干扰素诱导的自然杀伤细胞激活进一步增加。此外,西咪替丁增强了大多数黑色素瘤和结直肠癌患者外周血单个核细胞的干扰素诱导的杀伤细胞激活。